Emergent BioSolutions Reports Financial Results For Q3 2021.

EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2021.
QTRLY ADJUSTED LOSS PER SHARE $0.36.
QTRLY LOSS PER SHARE $0.61.
QTRLY TOTAL REVENUE $329 MILLION VERSUS $385.2 MILLION.
SEES 2021 TOTAL REVENUE $1,700 MILLION TO $1,800 MILLION.
SEES 2021 TOTAL ADJUSTED NET INCOME OF $315 MILLION TO $350 MILLION.
FY2021 REVENUE VIEW $1.80 BILLION -- REFINITIV IBES DATA.